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Abstract: We report results of a survey assessing patients’ knowledge about and attitudes 
towards depression in Parkinson’s disease (PD). 345 patients from 8 tertiary care centers 
responded (43% response rate). Overall, patients were relatively knowledgeable about depres-
sion and its occurrence in PD. However, many patients believed that depression is a normal 
reaction to the illness. While many respondents would be reluctant to initiate a discussion of 
depression during a clinical evaluation, most would feel comfortable talking about depression 
with their physician if he or she asked them questions about their mood. Based on the results 
of this survey, we recommend the following approach for physicians: (1) inform PD patients 
that, although a frequent occurrence, depression need not be accepted as a “normal reaction” 
to PD; and (2) routinely inquire about depressive symptoms rather than waiting for the patient 
to spontaneously report them.
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Introduction
Depression is common in PD with an estimated prevalence of 40%–50% (Mayeux 
et al 1986; Dooneif et al 1992; Tandberg et al 1996). Depression in PD has a negative 
impact on quality of life (Phillips 1999; Kuopio et al 2000; GPDS Steering Committee 
2001). There is a range of severity in depression associated with PD (Liu et al 1997) 
and evidence that even the minor forms of depression signiﬁ  cantly impair functional 
abilities (Liu et al 1997).
Evidence suggesting that depression in PD is probably a manifestation of underlying 
neurochemical and neuroanatomical alterations, rather than solely a reaction to disability, 
includes the following: (1) most studies have found patients with PD to be more depressed 
than other disabled patients matched for functional impairment (Wharburton 1967; Singer 
et al 1973; Ehmann et al 1990; Starkstein et al 1990; Menza et al 1994), (2) depression 
often antedates the parkinsonian motor symptoms (Horn 1974; Santamaria et al 1986; 
Ishihara 2006), and (3) there appears to be no clear-cut association between depression 
and stage of neurological illness (Cummings 1992). The precise relationship of depres-
sion to the underlying brain disease remains to be clariﬁ  ed.
There is evidence that depression in PD is under-diagnosed (GPDS Steering Com-
mittee 2001; Shulman et al 2002; Richard et al 2006) and under-treated (Weintraub et al 
2003; Ravina et al 2007). Both patients and physicians may have difﬁ  culty recognizing 
depression in PD due to potential overlap between signs and symptoms of depression 
and those of PD itself (Marsh et al 2006). In addition, there is some evidence to suggest 
that the frequency with which particular depressive symptoms manifest may be differ-
ent in patients with PD than in those without PD. For example, patients with PD tend 
to report fewer feelings of guilt or failure than patients without PD (Cummings 1992; Neuropsychiatric Disease and Treatment 2007:3(6) 904
Richard et al
Burn 2002). Also, the social stigma associated with depression 
may contribute to patients’ reluctance to seek help (Hirschfeld 
et al 1997; Sirey et al 2001; Roeloffs 2003).
PD patients must not only be knowledgeable of the 
symptoms of depression, they must be willing to discuss any 
signs of the symptoms with their physician. We conducted the 
following study to assess knowledge of and attitudes towards 
depression in a sample of patients with PD.
Methods
Eight US academic neurology/psychiatry clinics special-
izing in the treatment of PD were included in this survey 
study. Institutional Review Boards at each center approved 
the study. Each of the eight sites used a computer-generated 
list of 100 patients randomly selected from a larger list of 
PD patients attending their clinic for a total of 800 mailings. 
A letter from each site’s neurologist or psychiatrist describing 
the study was included. A cover letter provided instructions 
for completing the survey, an explanation of how others 
might help completing the survey if needed, and an empha-
sis on how the answers should reﬂ  ect the experiences and 
opinions of the PD patient.
We created the survey speciﬁ  cally for this study based on 
the current body of knowledge about depression in the setting 
of PD (Richard 2006, 2007; McDonald et al 2003). Our aim 
was to understand knowledge base and attitude of PD patients 
and not in the construction of a measurement scale per se. The 
survey contained 19 statements about depression (including 
those intended to assess knowledge about depression, the 
relationship between depression and PD and attitudes about 
discussing depression with others).
Subjects were instructed to respond to questions using a 
5-point Likert scale, a widely used psychometric response 
scale that measures attitude, providing a range of responses 
to a given question or statement (Likert 1932). Subjects could 
choose from one of the following responses for each item: 
strongly agree, agree, neither agree or disagree, disagree and 
strongly disagree.
The questionnaire requested that patients record their 
age, gender and duration of PD and answer yes or no to ﬁ  ve 
questions about their personal psychiatric history. Simple 
frequencies were tallied to represent how often respondents 
agree and disagree with the statements.
Results
Study respondent characteristics
Out of 800 surveys mailed, 49 were returned because the 
address was incorrect or the patient was deceased. A total 
of 345 surveys were completed and returned, for a response 
rate of 43%. The respondents ranged in age from 34–95 
years (mean age = 67.1 years) and 36% were female. 3.5% 
of the patients had been diagnosed with PD for less than one 
year, 38% for 1–5 years, 25.4% for 6–10 years and 32.4% 
for over 10 years. Thirty-two percent reported having been 
diagnosed with depression; 37.5% had been evaluated by 
a mental health professional, 45.6% had taken medication 
to help with their mood and 33.7% had a family member 
diagnosed with depression.
Survey responses
Responses to individual items are summarized in Table 1. 
In general, this group of respondents demonstrated that they 
were knowledgeable about many aspects of depression. 
Ideational symptoms and, to a slightly lesser extent, somatic 
symptoms of depression were recognized by the majority 
of respondents. The vast majority of patients knew that 
depression can be associated with reduced quality of life. 
The majority of patients realized that depression was com-
mon in PD but more than half considered it to be a normal 
reaction to the illness. While the majority of subjects were 
open to the idea of treatment, many responses indicated that 
a substantial minority perceived stigma surrounding depres-
sion. Many patients would be more comfortable to talk to 
their doctor than their family about depressive symptoms 
and would be more apt to discuss the issue if their physician 
initiated the conversation.
Conclusion
In general, our sample of PD patients was knowledgeable 
about depression but the majority of respondents believe 
that it is a normal reaction to the illness. There continues 
to be a stigma surrounding depression, even among this 
relatively knowledgeable group of patients. Many patients 
would be reluctant to talk about depression with their 
family or friends. PD patients may be hesitant to bring up 
depression with their physicians but would be willing to 
talk about symptoms of depression when the discussion is 
physician initiated.
There are several methodological limitations to our 
study that should be considered when interpreting the 
results. First, our group of respondents is likely to represent 
a highly selective sample of PD patients. Questionnaires 
were mailed only to patients at tertiary care academic and 
research-focused centers and slightly less than half returned 
completed surveys. Approximately one-third of responders 
reported having been diagnosed with depression. Thus, our Neuropsychiatric Disease and Treatment 2007:3(6) 905
Depression in PD survey
sample may be better informed about PD and depression 
than the typical PD patient. Second, our survey was created 
speciﬁ  cally for this study and has not undergone validity and 
reliability testing. Third, this was an anonymous self-report 
survey and objective evaluations were not conducted. We 
know that the average age and gender distribution was typical 
of PD and that there was a fairly evenly distributed range of 
disease duration. However, we do not have detailed clinical 
information (eg, motor, cognitive or psychiatric status) to 
consider when interpreting our results.
Future research may provide data with which to draw 
more deﬁ  nitive conclusions regarding the knowledge and 
attitudes about depression in PD. Such studies might include 
administration of the questionnaire to other populations (eg, 
community sample of PD patients, healthy controls) and 
direct assessment of patients in order to correlate survey 
responses with clinical characteristics. However, the results 
of this study do provide data to support the following rec-
ommendations to physicians: (1) inform PD patients that 
depression, while common in PD, is an abnormal emotional 
state that can be diagnosed and treated; and (2) remember 
to inquire about depressive symptoms when treating PD 
patients.
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